Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Abnormal chest x-ray, consistent with active opportunistic infection.
• •Hypersensitivity to thymopentin.
• •Significant chronic underlying medical illness.
• •Grade 2 or worse peripheral neuropathy.
• •Concurrent Medication:
• •Excluded:
• •HIV vaccines.
• •Investigational or non-FDA approved medication.
• •Immunomodulatory therapies.
• •Experimental therapies.
• •Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC.
• •Patients with the following prior conditions are excluded:
• •Herpes zoster (within the past year).
• •Recurrent (\> one episode) oral candidiasis (confirmed).
• •Vulvovaginal candidiasis (persistent, frequent, or poorly responsive to therapy).
• •Bacillary angiomatosis.
• •Listeriosis.
• •Idiopathic thrombocytopenia purpura.
• •Prior Medication:
• •Excluded at any time prior to study entry:
• •More than one dose of thymopentin.
• •Excluded within 30 days prior to study entry:
• •HIV vaccines.
• •Investigational or non-FDA approved medication.
• •Immunomodulatory therapies.
• •Experimental therapies.
• •Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC.
• •Required:
• •Prior AZT (\>= 300 mg/day) for at least 6 months; on current regimen (any combination of approved nucleoside analogues) for at least 4 weeks.
• •Significant active alcohol or drug abuse.